Disseminated adenovirus disease after allogeneic hematopoietic stem cell transplantation (HSCT) is lethal in most cases, especially when it develops as fulminant hepatic failure. We encountered a patient who developed fulminant hepatic failure caused by adenovirus infection. She did not show manifestations of graftversus-host disease and the results of serum tests for viral infection were all negative. Abdominal computed tomography (CT) findings were consistent with peliosis hepatitis. She died of fulminant hepatic failure, however, and pathological examinations of the liver specimen obtained after her death revealed adenovirus infection. In this report, we review the clinical characteristics and imaging findings of fulminant hepatic failure caused by adenovirus infection.
Introduction
Adenovirus infection after allogeneic hematopoietic stem cell transplantation (HSCT) is associated with high transplant-related mortality. Adenovirus infection is not infrequently observed after allogeneic HSCT. In 1980's, adenovirus was reported to be isolated from approximately 5% of patients undergoing bone marrow transplantation (1) . Recently, weekly monitoring by enzyme-linked immunoassay (ELISA) for adenovirus antigen and polymerase chain reaction (PCR) for adenovirus DNA revealed that the incidence of adenovirus infection was 29% (2) . The results of nested PCR for adenovirus DNA using samples from peripheral blood (PB), stool, urine, and throat were positive in 27% of patients after allogeneic HSCT (3) . Another retrospective study reported that adenovirus infection was detected in 11.5% of allogeneic HSCT recipients (4) . The risk factors for the development of adenovirus infection were graftversus-host disease (GVHD) and the presence of adenovirus antibody in the donor (1, 2) .
The clinical course of adenovirus infection ranges from subclinical reactivation to fatal disseminated adenovirus disease. Shields et al (1) isolated adenovirus from 51 of 1,051 patients undergoing marrow transplantation and invasive infection was histologically confirmed in 10 of the 51 patients, including those with hepatitis. We encountered a patient who developed fulminant hepatic failure caused by adenovirus infection after allogeneic HSCT. Abdominal computed tomography (CT) findings of this patient were unusual and resembled those of peliosis hepatitis. We could not diagnose it as adenovirus hepatitis before her death. Herein, we report the patient characteristics and review the clinical and imaging findings of fulminant adenovirus hepatic failure.
Case Report

Clinical course
A 52-year-old female developed aplastic anemia. Although she received cyclosporine (CSA) and methenolone acetate for 3 years, her pancytopenia gradually progressed. Then, she received immunosuppressive treatment with CSA and anti-thymocyte globulin (ATG), once with horse ATG (Lymphoglobulin, Institut Pasteur Merieux; Lyon, France) and thereafter with rabbit ATG (Zetbulin, ATG-F; Fresenius, Munich, Germany); however, these treatments were ineffective. Her white blood cell count decreased to 1.29×10 9 /L with 48% neutrophils and she became transfusion dependent for red blood cells and platelets. Therefore, she decided to undergo allogeneic HSCT when she was 58 years old.
The conditioning regimen consisted of rabbit ATG (Thymoglobulin, ATG-G, Genzyme; Cambridge, MA, USA) at 2.5 mg/kg/day from day -5 to day -2, fludarabine at 30 mg/ m 2 /day from day -5 to day -2, cyclophosphamide at 25 mg/ kg/day from day -5 to day -2, and total body irradiation at 2 Gy on day -1 (5). She received allogeneic bone marrow transplantation from an HLA-matched unrelated male donor. Bone marrow graft including 4.84×10 8 all nucleated cells per recipient body weight (kg) was infused on day 0. Prophylaxis against GVHD included CSA at 3 mg/kg/day in combination with methotrexate at 10 mg/m 2 on day 1 and 7 mg/m 2 on days 3, 6, and 11. The dose of CSA was adjusted to maintain the blood level at 500 ng/mL (6) . Prophylaxis against bacterial, fungal and Pneumocystis jiroveci infection consisted of levofloxacin, fluconazole, and pentamidine inhalation. Prophylaxis against herpes simplex virus and varicella zoster virus infection was performed with acyclovir at 500 mg/day intravenously or at 1,000 mg/day orally from day -7 to 35, followed by long-term low-dose (200 mg/day) oral administration (7, 8) . G-CSF (filgrastim) at 300 μg/ body/day was intravenously administered until neutrophil recovery was achieved. Engraftment, defined as a neutrophil count of more than 500/mm 3 for 3 consecutive days, was achieved on day 18. Bone marrow aspiration on day 29 showed complete donor-type chimerism by sex-chromosome fluorescent in situ hybridization (FISH). Grade II acute GVHD limited to the skin was observed on day 19, and it was controlled with topical steroid alone. Cytomegalovirus (CMV) antigenemia assay using C10/C11 antibody became positive on day 28 after HSCT and preemptive treatment with ganciclovir (5-10 mg/kg/day) was initiated (9) . Highgrade CMV antigenemia of more than 50 positive cells per 2 slides persisted until day 70, but no CMV disease was detected.
On day 79, she complained of fever and fatigue. Despite antibacterial treatment with moxifloxacin, high fever persisted and she presented with sore throat. In addition, CMV reactivation was detected again and preemptive treatment with GCV was resumed. No other abnormalities were found in physical examination except for swelling of pharynx. Complete blood count revealed a white blood count (WBC) of 1.56×10 3 /μL, hemoglobin level of 8.7 g/dL, and platelet count of 39×10 3 /μL. Flow cytometric analysis of peripheral blood showed a persistently low number of CD3 + CD4
+ cells and CD3 + CD8 + cells (2 and 37/μL, respectively) on day 91. All microbiological studies were negative including culture of blood, sputum, urine, stool, and spinal fluid. CT of the neck and chest also revealed no significant findings. However, despite the use of various antibacterial and antifungal agents in addition to GCV, her fever persisted ( Fig. 1 ). Although she had no abdominal symptoms, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels on day 96 increased to 94 mU/mL and 64 mU/mL, respectively. We performed abdominal ultrasonography (US), which showed a hypoechoic lesion in the liver. At that time, we suspected a fungal or protozonal infection, and we administered liposomal amphotericin B and metronidazole. We also performed immediate abdominal contrast-enhanced CT, which revealed multiple oval-shaped low-density lesions from a few millimeters to about 3 cm in diameter. They showed slow but homogeneously centripetal enhancement, similar to that observed in hemangioma (Fig. 2) . Peliosis hepatitis was strongly suspected based on the findings of the CT scan, but it was not compatible with the clinical course. Sinusoidal obstruction syndrome (SOS) was unlikely, as she did not have any other symptoms of SOS including body weight gain or right upper quadrant pain. On day 98, the serum ALT and AST level increased to 178 U/L and 121 U/L, respectively (Fig. 1) . We analyzed various serum markers for viral infection. She was positive for HBsAb and negative for HBsAg, HBV DNA, HCV-Ab, and HIV. Her serum IgG titers for HSV and VZV were positive and the corresponding serum IgM titers were negative. Further, CMV antigenemia had decreased with GCV therapy. The PCR for adenovirus DNA using whole blood sample was positive, while adenovirus was not detected in the nasopharyngeal swab by direct immunofluorescence. PCR for EB virus DNA using whole blood sample was also positive (1.8×10 3 copies/10 6 cells). Thereafter, the patient's liver function rapidly progressed to fulminant hepatic failure with a peak in AST and ALT levels of 6,800 U/L and 2,400 U/L, respectively, on day 106. She developed grade II hepatic encephalopathy on day 108. In addition, the prothrombin time was elongated to 43.4% on day 108, 33.3% on day 109, and 26.9% on day 110. Although we started plasmapheresis, she died of fulminant hepatic failure on day 109. All blood, stool, and urine cultures were persistently negative for bacteria and fungi before her death. Chronic GVHD was never observed through- 
Pathological findings
Pathological examinations using the liver specimen obtained percutaneously under an ultrasound-guided procedure after her death revealed large, random foci of hepatocytic necrosis (Fig. 3) . The multiple oval-shaped low-density lesions detected by CT scan were thought to be hepatic necrosis. Although mild inflammation was present, there was no significant inflammatory response suggesting acute GVHD. Intranuclear inclusions with characteristic Cowdry bodies and chromatin margination were found in some hepatocytes. Immunostaining for adenovirus (MAB805, blend of clones 20/11 and 2/6; CHEMICIN International Inc., Temecula, CA, USA) showed diffusely positive nuclear staining, while those for CMV and EB virus were negative.
Discussion
The main causes of liver injury after HSCT vary depending on the timing after SCT. Sinusoidal obstruction syndrome and drug-induced hepatotoxicity are frequently observed in the first few weeks after SCT. Subsequently, acute GVHD, viral infection, chronic GVHD, and nodular regenerative hyperplasia develop (10) . Adenovirus is one of the causes of fulminant hepatic failure after HSCT. Acute or fulminant adenovirus hepatic failure is not an uncommon complication after HSCT. As shown in Table 1 , however, there are differences in the timing after SCT, symptoms, and speed of progression.
Adenoviral disease can be diagnosed by histology, immunocytochemistry and culture of biopsied specimen. However, its diagnosis is hampered by the difficulty to obtain an appropriate specimen. In particular, liver biopsy is difficult to perform due to the high risk of bleeding. Therefore, imaging studies may be useful if there are some specific findings for adenovirus hepatitis. To date, there have been few reports on the imaging findings of severe liver injury after HSCT. SOS after HSCT shows specific Doppler sonography findings, including reversed or "to and fro" flow in the portal vein and/or a decreased flow in the portal vein (11) . However, no specific findings on imaging studies have been reported thus far about adenovirus hepatitis after HSCT. As shown in Table 2 , the results of imaging studies of adenovirus hepatitis after HSCT have been described in 3 patients. One of the 3 patients showed diffuse nonspecific changes by ultrasound and magnetic resonance scans of the liver (12), while the other 2 showed no abnormality (13, 14) . With regard to solid organ transplantation recipients, Gupta et al.
reported adenoviral hepatitis in a cardiac transplant recipient (15) . Abdominal CT scan showed multiple indeterminate low-attenuation masses in the liver. Similarly, Saad et al described a patient with adenovirus hepatitis after an orthotopic liver transplantation (16) . CT scans of the liver showed multiple low-density ill-defined lesions. Among hematological disorder patients other than HSCT recipients, the abdominal CT scan of an 84-year-old man with B-cell lymphoma who developed adenovirus-induced acute liver failure showed innumerable small hypoattenuating lesions, which probably corresponded to the areas of hepatic necrosis observed in autopsy ( The current patient also showed multiple hypoattenuating lesions mimicking peliosis hepatitis on CT scan. Peliosis hepatitis is a rare condition characterized by multiple small blood-filled spaces in the liver parenchyma. CT scan shows oval-shaped lesions that are homogeneously enhanced after intravenous injection of contrast agents (19) . The liver specimen obtained after her death revealed that these lesions correspond to areas of hepatic necrosis, as previously pointed out in some cases.
We conclude that adenoviral hepatitis should be considered as a possible cause of liver injury in allogeneic HSCT recipients with multiple low-density lesions of the liver observed in the CT scan, although such findings are not specific to adenovirus infection. Accumulation of imaging findings of adenovirus hepatitis is necessary to determine the characteristic and diagnostic imaging findings of acute or fulminant adenovirus hepatic failure.
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